Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs

被引:18
|
作者
DeAngelo, Jessica [1 ]
Jarrell, Daniel [1 ]
Cosgrove, Richard [1 ]
Camamo, James [1 ]
Edwards, Christopher [1 ]
Patanwala, Asad E. [2 ]
机构
[1] Banner Univ Med Ctr Tucson, Dept Pharm Serv, Tucson, AZ USA
[2] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Tucson, AZ USA
关键词
anticoagulants; warfarin; blood coagulation factors; hemorrhage; INTERNATIONAL NORMALIZED RATIO; CONSENSUS GUIDELINES; THROMBOSIS;
D O I
10.1097/MJT.0000000000000643
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting. It has been hypothesized that 3-PCC may be less effective than 4-PCC because of relatively lower factor VII content. Study Question: The primary objective of this study was to compare international normalized ratio (INR) reversal between 3-PCC and 4-factor PCC (4-PCC) in warfarin-treated patients. The secondary objectives include comparing blood product use, total reversal costs, and cost-effectiveness between the groups. Study Design: This was a retrospective cohort study conducted in 2 affiliated, academic institutions in the United States. Consecutive adult patients who received 3-PCC or 4-PCC for warfarin reversal were included. Measures and Outcomes: The primary outcome was adequate INR reversal defined as a final INR <= 1.5. Secondary outcomes were the utilization of plasma, red blood cells and platelets, reversal costs, and the cost-effectiveness ratio. Results: There were 89 patients who were included in the overall cohort (3-PCC = 57, 4-PCC = 32). Adequate INR reversal occurred less commonly with 3-PCC (45.6%) compared with 4-PCC (87.5%) (P < 0.001). There was no significant difference in the proportion of patients who received plasma (32% vs. 28%, P = 0.813), red blood cells (37% vs. 47%, P = 0.377), or platelets (16% vs. 28%, P = 0.180) between the 3-PCC and 4-PCC groups, respectively. The median reversal cost of 3-PCC ($3663) was lower than 4-PCC ($5105) (P = 0.001). The cost-effective ratio favored 4-PCC ($5105/87.5% = $5834) compared with 3-PCC ($3663/45.6% = $8033). Conclusions: Four-PCC was more effective than 3-PCC with regard to INR reversal in patients taking warfarin, but blood product use was similar. Although 4-PCC is associated with increased reversal costs, it may be cost-effective in terms of INR reversal.
引用
收藏
页码:E326 / E332
页数:7
相关论文
共 50 条
  • [31] CHARACTERIZING THE USE OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE
    Pajoumand, Mehrnaz
    Chaney, Whitney
    Mueller, Scott
    Shafeeq, Hira
    Daley, Mitchell
    Stump, Brian
    Hines, Michelle
    Rech, Megan
    Stein, Deborah
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 266 - 266
  • [32] Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis
    Greta Astrup
    Preeyaporn Sarangarm
    Allison Burnett
    Journal of Thrombosis and Thrombolysis, 2018, 45 : 300 - 305
  • [33] Evaluation of a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal
    McMahon, Clare
    Halfpap, Joe
    Zhao, Qianqian
    Bienvenida, Ana
    Rose, Anne E.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (10) : 1230 - 1235
  • [34] Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage
    Sarode, Ravi
    Matevosyan, Karen
    Bhagat, Ramesh
    Rutherford, Cynthia
    Madden, Christopher
    Beshay, Joseph E.
    JOURNAL OF NEUROSURGERY, 2012, 116 (03) : 491 - 497
  • [35] A COMPARISON OF 3-FACTOR PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS IN WARFARIN-ASSOCIATED ICH
    Tucker, Natalie
    Cook, Ryan
    Cave, Brandon
    Jones, Morgan
    CRITICAL CARE MEDICINE, 2020, 48
  • [36] USE OF A 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR MANAGEMENT OF WARFARIN INDUCED MAJOR BLEEDING
    Dobesh, Paul
    Trevarrow, Brian
    Guiliano, Kristen
    Malinowski, Patricia
    Duncan, Cody
    Gundabolu, Krishna
    CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [37] 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF COAGULOPATHY IN LIVER FAILURE
    Morris, Kaleb
    Condeni, Melanie
    Bell, Carolyn
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 446 - 446
  • [38] Fixed dosing of 4-factor prothrombin complex concentrate for reversal of anticoagulation
    Jung, B.
    Johnson, B.
    Kreuziger, L. Baumann
    HAEMOPHILIA, 2019, 25 : 34 - 34
  • [39] Ischemic Stroke Symptoms After Warfarin Reversal With 4-Factor Prothrombin Complex Concentrate Case Report
    Carson, Laura
    Price, John E., II
    HOSPITAL PHARMACY, 2020, 55 (01) : 69 - 71
  • [40] Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding
    Stewart, William S.
    Pettit, Herbert
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2013, 31 (08): : 1251 - 1254